You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-1674-ESGO Should delayed debulking/cytoreductive surgery be offered to all advanced ovarian/fallopian tubal cancer patients that did not have surgery?

Alerts

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-1674-ESGO Should delayed debulking/cytoreductive surgery be offered to all advanced ovarian/fallopian tubal cancer patients that did not have surgery?
Free
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address